{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:15:14Z","timestamp":1777569314116,"version":"3.51.4"},"reference-count":23,"publisher":"Cambridge University Press (CUP)","issue":"4","license":[{"start":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T00:00:00Z","timestamp":1408579200000},"content-version":"unspecified","delay-in-days":20,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:p>ISSUE:Although many patients with schizophrenia fail to respond adequately to trials of 2 or more antipsychotics, utilization of clozapine for these patients remains low, despite recommendations for its use by accepted treatment guidelines. Some experts estimate that 5\u201310 times more patients could benefit from clozapine than who are now receiving it. Learning how to manage the unique side effect profile of clozapine can potentially remove barriers to prescribing this agent and thus unlock its unique therapeutic efficacy for more patients.<\/jats:p>","DOI":"10.1017\/s1092852914000418","type":"journal-article","created":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T10:10:46Z","timestamp":1408615846000},"page":"279-281","source":"Crossref","is-referenced-by-count":17,"title":["Clozapine: Is Now the Time for More Clinicians to Adopt This Orphan?"],"prefix":"10.1017","volume":"19","author":[{"given":"Stephen M.","family":"Stahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,8,21]]},"reference":[{"key":"S1092852914000418_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60742-X"},{"key":"S1092852914000418_ref10","doi-asserted-by":"publisher","DOI":"10.1017\/S146114571100201X"},{"key":"S1092852914000418_ref14","article-title":"Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital","author":"Brown","journal-title":"CNS Spectr"},{"key":"S1092852914000418_ref3","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108100320"},{"key":"S1092852914000418_ref23","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12259"},{"key":"S1092852914000418_ref16","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11r06977"},{"key":"S1092852914000418_ref7","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.1.82"},{"key":"S1092852914000418_ref2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112443744"},{"key":"S1092852914000418_ref22","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbq137"},{"key":"S1092852914000418_ref18","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-7-200704030-00004"},{"key":"S1092852914000418_ref17","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12r08064"},{"key":"S1092852914000418_ref13","article-title":"Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study","author":"Volavka","journal-title":"CNS Spectr"},{"key":"S1092852914000418_ref6","doi-asserted-by":"publisher","DOI":"10.1017\/S109285291300014X"},{"key":"S1092852914000418_ref1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.4.600"},{"key":"S1092852914000418_ref21","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04495"},{"key":"S1092852914000418_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.10.014"},{"key":"S1092852914000418_ref12","article-title":"Augmentation of clozapine with amizulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high security hospital","author":"Hotham","journal-title":"CNS Spectr"},{"key":"S1092852914000418_ref19","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2004.031161"},{"key":"S1092852914000418_ref4","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.6.3.5"},{"key":"S1092852914000418_ref8","volume-title":"The Prescriber's Guide: Stahl's Essential Psychopharmacology","author":"Stahl","year":"2014"},{"key":"S1092852914000418_ref5","volume-title":"Stahl's Essential Psychopharmacology","author":"Stahl","year":"2013"},{"key":"S1092852914000418_ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.6.622"},{"key":"S1092852914000418_ref9","article-title":"Antipsychotics, mood stabilisers, and risk of violent crime","author":"Fazel","journal-title":"Lancet"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852914000418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T01:42:46Z","timestamp":1555897366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852914000418\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1092852914000418"],"URL":"https:\/\/doi.org\/10.1017\/s1092852914000418","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}